RiverVest invites you to read our latest newsletter, featuring:
- Portfolio Company Bluejay Therapeutics Acquired by Mirum
- Pharmaceuticals
- JPM 2026 Recap: Signals are Getting Clearer
- RiverVest Scientific Advisor Alessandro Sette to Receive Prestigious Immunology Award
- Could Excess Cortisol Be Driving Type 2 Diabetes Resistance?
- Portfolio News